PRESS RELEASE
News
-
-
-
-
PRESS RELEASE
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
Jaguar Health plans crofelemer approval pathway for breast and lung cancer based on phase 3 results. Join the investor webcast on August 13, 2024, for financial & corporate updates -
-
-
PRESS RELEASE
Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningf
Jaguar Health, Inc. issued a letter to shareholders regarding the upcoming webcast to review second-quarter earnings and clinical data from the recent phase 3 OnTarget trial of crofelemer for breast and lung cancer patients -
-
-
PRESS RELEASE
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Dr. Elisabetsky conducts research on plant-based medicines for mental health conditions. Jaguar out-licenses botanical drug for schizophrenia treatment to Magdalena Biosciences
